Peer-Reviewed Journal Details
Mandatory Fields
Payne, CM,Burke, LP,Cavanagh, B,O'Toole, D,Cryan, SA,Kelly, HM
2019
April
Pharmaceutical Research
Evaluation of the Immunomodulatory Effects of All-Trans Retinoic Acid Solid Lipid Nanoparticles and Human Mesenchymal Stem Cells in an A549 Epithelial Cell Line Model
Published
Optional Fields
all trans retinoic acid chronic obstructive pulmonary disease human mesenchymal stem cells immunomodulatory solid lipid nanoparticles OBSTRUCTIVE PULMONARY-DISEASE DRUG-DELIVERY IN-VITRO INFLAMMATORY CELLS CARRIERS NLC FORMULATION EMPHYSEMA RELEASE SLN TRANSPLANTATION
36
Purpose To investigate two potential strategies aimed at targeting the inflammatory pathogenesis of COPD: a small molecule, all trans retinoic acid (atRA) and human mesenchymal stem cells (hMSCs).Methods atRA was formulated into solid lipid nanoparticles (SLNs) via the emulsification-ultrasonication method, and these SLNs were characterised physicochemically. Assessment of the immunomodulatory effects of atRA-SLNs on A549 cells in vitro was determined using ELISA. hMSCs were suspended in a previously developed methylcellulose, collagen and beta-glycerophosphate hydrogel prior to investigating their immunomodulatory effects in vitro.Results SLNs provided significant encapsulation of atRA and also sustained its release over 72 h. A549 cells were viable following the addition of atRA SLNs and showed a reduction in IL-6 and IL-8 levels. A549 cells also remained viable following addition of the hMSC/hydrogel formulation - however, this formulation resulted in increased levels of IL-6 and IL-8, indicating a potentially pro-inflammatory effect.Conclusion Both atRA SLNs and hMSCs show potential for modulating the environment in inflammatory disease, though through different mechanisms and leading to different outcomes - despite both being explored as strategies for use in inflammatory disease. atRA shows promise by acting in a directly anti-inflammatory manner, whereas further research into the exact mechanisms and behaviours of hMSCs in inflammatory diseases is required.
10.1007/s11095-019-2583-x
Grant Details
Publication Themes